At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 7 enrolled
Drug / intervention
CBD Day 1 +2 moredrug
Likely dose
CBD Day 1 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain
In Brief
A Early Phase 1 clinical trial evaluating CBD Day 1, CBD Day 2, and 1 other intervention for Addiction. Completed, enrolled 7 participants across 1 site.
Detailed Summary
The overarching goal of this study is to evaluate the potential of Cannabidiol (CBD) as an adjunctive treatment for comorbid opioid use disorder (OUD) and chronic pain. This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of CBD on measures of pain and opioid craving in outpatients with OUD receiving methadone or buprenorphine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAddiction
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Early Ph 1CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartDec 2021
Primary CompletionJun 2024
TodayJul 2026
First PostedOct 13, 2021
Enrollment StartDec 8, 2021
Primary CompletionJun 28, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.7 years ago
Interventions
CBD Day 1drug
CBD 400mg
CBD Day 2drug
CBD 800mg
CBD Day 3drug
CBD 1200mg